Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors
| Autor: | David G, Oscier, Anne C, Gardiner, Sarah J, Mould, Sharron, Glide, Zadie A, Davis, Rachel E, Ibbotson, Martin M, Corcoran, Robert M, Chapman, Peter W, Thomas, J Adrian, Copplestone, Jenny A, Orchard, Terry J, Hamblin |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Male
Analysis of Variance Sex Characteristics Chromosomes Human Pair 12 Membrane Glycoproteins Chromosomes Human Pair 13 Chromosomes Human Pair 11 Immunoglobulin Variable Region Trisomy Genes p53 Prognosis ADP-ribosyl Cyclase 1 Antigens Differentiation Leukemia Lymphocytic Chronic B-Cell Survival Rate Blotting Southern NAD+ Nucleosidase Antigens CD Mutation Humans Female ADP-ribosyl Cyclase Immunoglobulin Heavy Chains Gene Deletion Proportional Hazards Models |
| Zdroj: | Blood. 100(4) |
| ISSN: | 0006-4971 |
| Popis: | This study evaluates the prognostic significance of genetic abnormalities (detected at or shortly after presentation), clinical stage, lymphocyte morphology, CD38 expression, and IGVH gene status in 205 patients with chronic lymphocytic leukemia (B-CLL). Deletion of chromosome 11q23, absence of a deletion of chromosome 13q14, atypical lymphocyte morphology, and more than 30% CD38 expression are significantly associated with the presence of unmutated IGVH genes. Advanced stage, male sex, atypical morphology, more than 30% CD38 expression, trisomy 12, deletion of chromosome 11q23, loss or mutation of the p53 gene, and unmutated IGVH genes are all poor prognostic factors in a univariate analysis. However, only 98% or more homology of IGVH genes to the germline sequence, loss or mutation of the p53 gene, and clinical stage retain prognostic significance in a multivariate analysis. The median survival of patients with mutated IGVH genes, unmutated IGVH genes, and loss or mutation of the p53 gene regardless of IGVH gene status is 310, 119, and 47 months, respectively. These data should facilitate the design of new trials for the management of patients presenting with advanced disease or poor prognosis early stage disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|